Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors

Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial Tumors

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers. However, activation of the immune system can occasionally cause life-threatening toxicity involving critical organs. Induction of immune-mediated toxicity is a significant concern for patients with thymic epit...

Full description

Bibliographic Details
Main Authors: Ballman, M. (Author), Chen, H. (Author), Donahue, R.N (Author), Gulley, J.L (Author), Gupta, S. (Author), Loehrer, P.J (Author), McAdams, M.J (Author), Mullenix, C. (Author), Poretta, T. (Author), Rajan, A. (Author), Schlom, J. (Author), Swift, S. (Author), Tsai, Y.-T (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
adverse event
human
Humans
Immune Checkpoint Inhibitors
immunotherapy
Immunotherapy
inflammatory arthritis
myositis
Myositis
neoplasm
Neoplasms
Neoplasms, Glandular and Epithelial
polymyalgia rheumatica
Polymyalgia Rheumatica
rheumatic polymyalgia
thymic epithelial tumors
thymoma
Thymus Neoplasms
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items